Abstract
Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development.
Original language | English |
---|---|
Pages (from-to) | 69-74 |
Number of pages | 6 |
Journal | Oncology |
Volume | 77 |
Issue number | SUPPL. 1 |
DOIs | |
Publication status | Published - Feb 2010 |
Keywords
- AKT
- Cetuximab
- MTOR
- Panitumumab
- Phosphoinositide 3-kinases
- PTEN
ASJC Scopus subject areas
- Cancer Research
- Oncology